Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus apatinib versus almonertinib alone as first-line treatment for EGFR-mutant advanced NSCLC
ChiCTR2100047453Phase 3Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of almonertinib and Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Progression-free survival, Overall survival and 6 more. Started Apr 2021; status: recruiting.
02
Drugs
almonertinibRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100047453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047453.